Short-course chemoprophylaxis for tuberculosis

Research output: Contribution to journalArticle

Abstract

The current practice of using INH for tuberculosis prevention is limited by the necessity for at least 6 months of therapy and the problem of INH- induced hepatitis, particularly in older individuals and those with chronic liver disease. Bacteriologic models suggest that, in their persistent form, tubercle bacilli are relatively resistant to INH but become more sensitive to other drugs. Similarly, animal models of latent tuberculosis have suggested that alternative, short-course combinations such as RIF/PZA may be effective, and clinical trials of that two-drug regimen are continuing. At the present time, 3 months of daily RIF, 2 months of RIF/PZA, and 3 months of rifabutin can be considered reasonable alternatives to INH in selected patients. Routine use of these agents in preference to INH cannot yet be endorsed, however, as the standard of care. Without highly effective vaccines for tuberculosis, an important strategy for breaking the cycle of tuberculosis transmission lies in inexpensive, convenient, and effective preventive therapy.

Original languageEnglish (US)
Pages (from-to)115-122
Number of pages8
JournalClinics in Chest Medicine
Volume18
Issue number1
DOIs
StatePublished - 1997

Fingerprint

Chemoprevention
Tuberculosis
Tuberculosis Vaccines
Rifabutin
Latent Tuberculosis
Standard of Care
Pharmaceutical Preparations
Bacillus
Hepatitis
Liver Diseases
Chronic Disease
Animal Models
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Short-course chemoprophylaxis for tuberculosis. / Bishai, William Ramses; Chaisson, Richard E.

In: Clinics in Chest Medicine, Vol. 18, No. 1, 1997, p. 115-122.

Research output: Contribution to journalArticle

@article{11d5eccda33744dcb1ae0aed280807ea,
title = "Short-course chemoprophylaxis for tuberculosis",
abstract = "The current practice of using INH for tuberculosis prevention is limited by the necessity for at least 6 months of therapy and the problem of INH- induced hepatitis, particularly in older individuals and those with chronic liver disease. Bacteriologic models suggest that, in their persistent form, tubercle bacilli are relatively resistant to INH but become more sensitive to other drugs. Similarly, animal models of latent tuberculosis have suggested that alternative, short-course combinations such as RIF/PZA may be effective, and clinical trials of that two-drug regimen are continuing. At the present time, 3 months of daily RIF, 2 months of RIF/PZA, and 3 months of rifabutin can be considered reasonable alternatives to INH in selected patients. Routine use of these agents in preference to INH cannot yet be endorsed, however, as the standard of care. Without highly effective vaccines for tuberculosis, an important strategy for breaking the cycle of tuberculosis transmission lies in inexpensive, convenient, and effective preventive therapy.",
author = "Bishai, {William Ramses} and Chaisson, {Richard E}",
year = "1997",
doi = "10.1016/S0272-5231(05)70360-9",
language = "English (US)",
volume = "18",
pages = "115--122",
journal = "Clinics in Chest Medicine",
issn = "0272-5231",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Short-course chemoprophylaxis for tuberculosis

AU - Bishai, William Ramses

AU - Chaisson, Richard E

PY - 1997

Y1 - 1997

N2 - The current practice of using INH for tuberculosis prevention is limited by the necessity for at least 6 months of therapy and the problem of INH- induced hepatitis, particularly in older individuals and those with chronic liver disease. Bacteriologic models suggest that, in their persistent form, tubercle bacilli are relatively resistant to INH but become more sensitive to other drugs. Similarly, animal models of latent tuberculosis have suggested that alternative, short-course combinations such as RIF/PZA may be effective, and clinical trials of that two-drug regimen are continuing. At the present time, 3 months of daily RIF, 2 months of RIF/PZA, and 3 months of rifabutin can be considered reasonable alternatives to INH in selected patients. Routine use of these agents in preference to INH cannot yet be endorsed, however, as the standard of care. Without highly effective vaccines for tuberculosis, an important strategy for breaking the cycle of tuberculosis transmission lies in inexpensive, convenient, and effective preventive therapy.

AB - The current practice of using INH for tuberculosis prevention is limited by the necessity for at least 6 months of therapy and the problem of INH- induced hepatitis, particularly in older individuals and those with chronic liver disease. Bacteriologic models suggest that, in their persistent form, tubercle bacilli are relatively resistant to INH but become more sensitive to other drugs. Similarly, animal models of latent tuberculosis have suggested that alternative, short-course combinations such as RIF/PZA may be effective, and clinical trials of that two-drug regimen are continuing. At the present time, 3 months of daily RIF, 2 months of RIF/PZA, and 3 months of rifabutin can be considered reasonable alternatives to INH in selected patients. Routine use of these agents in preference to INH cannot yet be endorsed, however, as the standard of care. Without highly effective vaccines for tuberculosis, an important strategy for breaking the cycle of tuberculosis transmission lies in inexpensive, convenient, and effective preventive therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030984274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030984274&partnerID=8YFLogxK

U2 - 10.1016/S0272-5231(05)70360-9

DO - 10.1016/S0272-5231(05)70360-9

M3 - Article

VL - 18

SP - 115

EP - 122

JO - Clinics in Chest Medicine

JF - Clinics in Chest Medicine

SN - 0272-5231

IS - 1

ER -